TG-1000 Phase III Trial Success for TaiGen

TaiGen Biotechnology, a pharmaceutical firm, has reported positive results from the phase III clinical trial of its influenza antiviral drug, TG-1000. The study, conducted in partnership with Joincare Pharmaceutical, demonstrated that TG-1000 significantly reduced the time required for influenza symptoms to subside when compared to a placebo. The drug also showed a favorable safety profile, with no serious adverse effects observed during the trial.

The pivotal phase III study was a multi-center, randomized, and double-blinded trial that aimed to assess the efficacy and safety of TG-1000 in treating uncomplicated acute influenza in both adults and adolescents. A total of 752 participants were evenly divided into two groups, one receiving TG-1000 and the other a placebo. The majority of the patients involved in the trial were infected with influenza virus A, in line with the influenza surveillance data from China.

The primary outcome measure of the study was the median time to symptom alleviation, which was notably shorter in the TG-1000 group compared to the placebo group, highlighting the drug's effectiveness in treating influenza. The secondary endpoints, which are still under analysis, include the assessment of antiviral efficacy, symptom relief, and the prevention of influenza-related complications.

TaiGen's Chairman and CEO, Kuo-Lung Huang, expressed optimism regarding the results, noting the growing need for innovative treatments in light of the increasing coexistence of influenza viruses and humans. He also pointed out the significant market potential for new influenza medications, with sales in mainland China reaching over RMB 6 billion in 2023.

TaiGen, established in 2001 and listed on the Taiwan OTC Stock Market in 2014, is a fully integrated pharmaceutical company focused on developing innovative small molecule drugs, particularly in the area of anti-infective research. Its flagship product, Taigexyn® (Nemonoxacin), a non-fluorinated quinolone antibiotic, has received marketing approvals in several regions, including Taiwan, mainland China, and Russia. The successful completion of the TG-1000 phase III trial marks another milestone for the company in its pursuit of advancing novel treatments for infectious diseases.